drugset
drugset / Trial / NCT07073014

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

NCT07073014 ↗

Phase 3 Enrolling by invitation 140 enrolled BioMarin Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH

Timeline

Start
2025-06-20
Primary completion
2040-12
Completion
2040-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vosoritide Peptide — —

Indications

hypochondroplasia